SCHEMBL6930071

SCHEMBL6930071

Nc1ccc(O)c(-n2nc3ccc(Cl)cc3n2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 10/20 0.58
KMT2A Q03164 10/20 0.58
NPC1 O15118 11/20 0.56
RAB9A P51151 9/20 0.56
MAPT P10636 5/20 0.56
KDM4E B2RXH2 4/20 0.56
ATM Q13315 3/20 0.56
LMNA P02545 1/20 0.45
ALDH1A1 P00352 5/20 0.44
HPGD P15428 3/20 0.44
HSD17B10 Q99714 3/20 0.44
TP53 P04637 2/20 0.44
CASP1 P29466 2/20 0.44
CASP7 P55210 2/20 0.44
ALOX15 P16050 2/20 0.44
APAF1 O14727 1/20 0.44
STAT1 P42224 1/20 0.44
POLB P06746 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11418479 0.89 NPC1 (0.51) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL6930714 0.88 NPC1 (0.56) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL508298 0.82 NPC1 (0.65) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL29444885 0.82 NPC1 (0.65) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL698631 0.82 NPC1 (0.69) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL30130370 0.82 NPC1 (0.69) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL21023563 0.81 MEN1 (0.64) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL27322664 0.81 MEN1 (0.42) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL3782539 0.80 POLB (0.50) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL29377081 0.80 POLB (0.50) MEN1KMT2ANPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0944624-B1 INSOLUBLE S-TRIAZINE DERIVATIVES AND THEIR USE AS UV FILTERS OREAL (FR) 2003-11-05 EP disclosed
CN-1123572-C Insoluble s-triazine derivatives, process for their preparation, compositions containing them and their use OREAL (FR) 2003-10-08 CN disclosed
US-6517742-B1 2-(butyl 4'-ylaminobenzoate)-4,6-bis((1,3,3,3-tetramethyl-1 -((trimethylsilyl)oxy)disiloxanyl)propyl-3-ylamino)-s-triazine; s-triazine derivatives substituted by at least one silicone group; from cyanuric chloride L'OREAL (FR) 2003-02-11 US disclosed
US-6361764-B2 ULTRAVIOLET LIGHT SCREENING AGENTS; COSMETICS SOCIETE L'OREAL S.A. (FR) 2002-03-26 US disclosed
US-20020010179-A1 Novel insoluble S-triazine derivatives, process for their preparation, compositions containing them and uses thereof RICHARD HERVE (FR) 2002-01-24 US disclosed
CN-1240446-A Insoluble s-triazine derivatives and their use as UV absorbers OREAL (FR) 2000-01-05 CN disclosed
EP-0944624-A1 INSOLUBLE S-TRIAZINE DERIVATIVES AND THEIR USE AS UV FILTERS L'OREAL (FR) 1999-09-29 EP disclosed
EP-0841341-B1 Sunscreen agents, and cosmetic compositions containing them OREAL (FR) 1999-04-07 EP disclosed
WO-1998025922-A1 INSOLUBLE S-TRIAZINE DERIVATIVES AND THEIR USE AS UV FILTERS L'OREAL (FR) 1998-06-18 WO disclosed
EP-0841341-A1 Sunscreen agents, and cosmetic compositions containing them L'OREAL (FR) 1998-05-13 EP disclosed
US-4719248-A BENZOTRIAZOLE UNSATURATED AMIDE BAUSCH & LOMB INCORPORATED (US) 1988-01-12 US disclosed
EP-0221630-A2 Ultraviolet blocking agents for contact lenses BAUSCH & LOMB INCORPORATED (US) 1987-05-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010179-A1 Novel insoluble S-triazine derivatives, process for their preparation, compositions containing them and uses thereof TST, TYR, TPST2 MEN1 4386/4885KMT2A 1547/4885NPC1 3874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.